Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock, par value $0.00001 per share
-
Shares outstanding
-
108M
-
Number of holders
-
131
-
Total 13F shares, excl. options
-
71M
-
Shares change
-
-501K
-
Total reported value, excl. options
-
$736M
-
Value change
-
+$5.84M
-
Put/Call ratio
-
1.21
-
Number of buys
-
65
-
Number of sells
-
-67
-
Price
-
$10.37
Significant Holders of Aclaris Therapeutics, Inc. - Common Stock, par value $0.00001 per share (ACRS) as of Q2 2023
186 filings reported holding ACRS - Aclaris Therapeutics, Inc. - Common Stock, par value $0.00001 per share as of Q2 2023.
Aclaris Therapeutics, Inc. - Common Stock, par value $0.00001 per share (ACRS) has 131 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 71M shares
of 108M outstanding shares and own 65.52% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (7.64M shares), BlackRock Inc. (5.59M shares), RA CAPITAL MANAGEMENT, L.P. (4.4M shares), Rock Springs Capital Management LP (3.96M shares), Bain Capital Life Sciences Investors, LLC (3.4M shares), BVF INC/IL (3.36M shares), VANGUARD GROUP INC (3.33M shares), BRAIDWELL LP (2.9M shares), Foresite Capital Management IV, LLC (2.81M shares), and CITADEL ADVISORS LLC (2.61M shares).
This table shows the top 131 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.